button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

lung cancer : non small cell (NSCLC) lung cancer : non small cell (NSCLC)

locally advanced NSCLC - (neo)adjuvant (NA) locally advanced NSCLC - (neo)adjuvant (NA)

versus placebo plus SoC
nivolumab plus SoC vs. placebo plus SoC 1 ---

laNSCLC - M - all population locally advanced NSCLC - maintenance (M) laNSCLC - M - all population

versus placebo
durvalumab alone vs. placebo 1 1.0better0.35.098 %1.0better0.35.0100 %-

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus placebo plus SoC
sintillimab plus SoC vs. placebo plus SoC 1 1.0better0.35.099 %1.0better0.35.0100 %-
versus Standard of Care (SoC)
cemiplimab vs. Standard of Care (SoC) 1 1.0better0.35.0100 %1.0better0.35.0100 %-
durvalumab alone vs. Standard of Care (SoC) 1 1.0better0.35.068 %--

mNSCLC - L1 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 negative

versus pemetrexed plus platin
nivolumab plus SoC vs. pemetrexed plus platin 1 1.0better0.35.097 %1.0better0.35.099 %-

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 3 1.0better0.35.093 %1.0better0.35.099 %-
cemiplimab vs. Standard of Care (SoC) 1 1.0better0.35.0100 %1.0better0.35.0100 %-
durvalumab alone vs. Standard of Care (SoC) 1 1.0better0.35.096 %1.0better0.35.076 %-
nivolumab alone vs. Standard of Care (SoC) 2 1.0better0.35.073 %1.0better0.35.093 %-
pembrolizumab alone vs. Standard of Care (SoC) 4 1.0better0.35.099 %1.0better0.35.078 %-

mNSCLC - L1 - TMB>10Mb metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - TMB10Mb

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

versus atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. atezolizumab plus carboplatin plus nab-paclitaxel 1 1.0better0.35.098 %1.0better0.35.0100 %-
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 1.0better0.35.0100 %1.0better0.35.0100 %-
atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 1.0better0.35.096 %1.0better0.35.089 %-

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 2 1.0better0.35.099 %1.0better0.35.0100 %-
versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 1.0better0.35.098 %1.0better0.35.0100 %-
versus pemetrexed plus platin
atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin 1 1.0better0.35.096 %1.0better0.35.0100 %-
pembrolizumab and pemetrexed plus platin vs. pemetrexed plus platin 1 1.0better0.35.061 %1.0better0.35.099 %-
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 1.0better0.35.0100 %1.0better0.35.0100 %-

squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population

versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 1.0better0.35.092 %1.0better0.35.0100 %-
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 1.0better0.35.0100 %1.0better0.35.0100 %-

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)

mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population

versus docetaxel
atezolizumab alone vs. docetaxel 2 1.0better0.35.0100 %1.0better0.35.079 %-
avelumab alone vs. docetaxel 1 1.0better0.35.087 %1.0better0.35.094 %-
nivolumab alone vs. docetaxel 1 1.0better0.35.0100 %1.0better0.35.099 %-
Tislelizumab vs. docetaxel 1 ---

mNSCLC - L2 - EGFR mutant metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - EGFR mutant

versus osimertinib
durvalumab plus osimertinib vs. osimertinib 1 1.0better0.35.084 %1.0better0.35.055 %-

mNSCLC - L2 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 negative

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive

versus docetaxel
atezolizumab alone vs. docetaxel 1 1.0better0.35.0100 %1.0better0.35.095 %-
avelumab alone vs. docetaxel 1 1.0better0.35.083 %1.0better0.35.053 %-
pembrolizumab (10mg/kg) vs. docetaxel 2 1.0better0.35.0100 %1.0better0.35.099 %-
pembrolizumab (2mg/kg) vs. docetaxel 2 1.0better0.35.0100 %1.0better0.35.094 %-
versus Standard of Care (SoC)
durvalumab alone vs. Standard of Care (SoC) 1 1.0better0.35.099 %1.0better0.35.096 %-

non squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) non squamous cell - mNSCLC - L2 non squamous - mNSCLC - L2 - all population

versus docetaxel
nivolumab alone vs. docetaxel 1 1.0better0.35.0100 %1.0better0.35.082 %-

squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) squamous cell - mNSCLC - L2 squamous - mNSCLC - L2 - all population

versus docetaxel
nivolumab alone vs. docetaxel 1 1.0better0.35.0100 %1.0better0.35.0100 %-

NSCLC neoadjuvant setting NSCLC neoadjuvant setting

versus placebo plus SoC
nivolumab plus SoC vs. placebo plus SoC 1 ---

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons